國家衛生研究院 NHRI:Item 3990099045/15002

NHRI > Institute of Biomedical Engineering and Nanomedicine > Chia-Wen Wu > Periodical Articles > Item 3990099045/15002

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15002

Title:	Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders
Authors:	Yu, YS;AboulFotouh, K;Xu, H;Williams, G;Suman, J;Cano, C;Warnken, ZN;K, CWW;Williams Iii, RO;Cui, Z
Contributors:	Institute of Biomedical Engineering and Nanomedicine
Abstract:	Intranasal vaccination by directly applying a vaccine dry powder is appealing. However, a method that can be used to transform a vaccine from a liquid to a dry powder and a device that can be used to administer the powder to the desired region(s) of the nasal cavity are critical for successful intranasal vaccination. In the present study, using a model vaccine that contains liposomal monophosphoryl lipid A and QS-21 adjuvant (AdjLMQ) and ovalbumin (OVA) as a model antigen, it was shown that thin-film freeze-drying can be applied to convert the liquid vaccine containing sucrose at a sucrose to lipid ratio of 15:1 (w/w) into dry powders, in the presence or absence of carboxymethyl cellulose sodium salt (CMC) as a mucoadhesive agent. Ultimately, the thin-film freeze-dried AdjLMQ/OVA vaccine powder containing 1.9% (w/w) of CMC (i.e., TFF AdjLMQ/OVA/CMC(1.9%) powder) was selected for additional evaluation because the TFF AdjLMQ/OVA/CMC(1.9%) powder was mucoadhesive and maintained the integrity of the antigen and the physical properties of the vaccine. Compared to the TFF AdjLMQ/OVA powder that did not contain CMC, the TFF AdjLMQ/OVA/CMC(1.9%) powder had a lower moisture content and a higher glass transition temperature. In addition, the TFF AdjLMQ/OVA/CMC(1.9%) thin films were relatively thicker than the TFF AdjLMQ/OVA thin films without CMC. When sprayed with Aptar Pharma's Unidose Powder Nasal Spray System (UDSP), the TFF AdjLMQ/OVA powder and the TFF AdjLMQ/OVA/CMC(1.9%) powder generated similar particle size distribution curves, spray patterns, and plume geometries. Importantly, after the TFF AdjLMQ/OVA/CMC(1.9%) powder was sprayed with the UDSP nasal device, the integrity of the OVA antigen and the AdjLMQ liposomes did not change. Finally, a Taguchi L4 orthogonal array was applied to identify the optimal parameters for using the UDSP device to deliver the TFF AdjLMQ/OVA/CMC(1.9%) vaccine powder to the middle and lower turbinate and the nasopharynx regions in both adult and child nasal replica casts. Results from this study showed that it is feasible to apply the TFF technology to transform a nasal vaccine candidate from liquid to a dry powder and then use the UDSP nasal device to deliver the TFF vaccine powder to the desired regions in the nasal cavity for intranasal vaccination.
Date:	2023-04-29
Relation:	International Journal of Pharmaceutics. 2023 Apr 29;Article number 122990.
Link to:	http://dx.doi.org/10.1016/j.ijpharm.2023.122990
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0378-5173&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001006417400001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85159131872
Appears in Collections:	[Chia-Wen Wu] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB37127138.pdf		3805Kb	Adobe PDF	220	View/Open

Loading...